SCHEMBL3498640

SCHEMBL3498640

CCOC(=O)c1cc2cc(-c3ccc(OC)cc3)ccc2s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
ALDH1A1 P00352 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
KDM4E B2RXH2 2/20 0.52
HPGD P15428 2/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
TP53 P04637 1/20 0.52
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
HSD17B10 Q99714 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
F9 P00740 3/20 0.49
F10 P00742 3/20 0.49
CLK1 P49759 4/20 0.49
GAA P10253 3/20 0.49
DYRK1A Q13627 2/20 0.49
GRM6 O15303 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1391285 0.89 CLK1 (0.60) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL3500033 0.88 MAPT (0.56) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL3499504 0.86 F9 (0.47) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL3500699 0.86 F9 (0.49) MAPTALDH1A1NPC1RAB9ATP53
SCHEMBL3498454 0.86 MAPK14 (0.54) MAPTALDH1A1KDM4EHPGDNPC1
SCHEMBL3498021 0.86 MAPT (0.50) MAPTALDH1A1KDM4EHPGDF9
SCHEMBL3496798 0.84 PRKCI (0.46) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL3499196 0.82 MAPT (0.53) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL3496932 0.82 CLK1 (0.55) F9F10CLK1DYRK1ADYRK1B
SCHEMBL1391041 0.81 MAPT (0.53) MAPTALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 MAPT 4820/4885ALDH1A1 3047/4885MEN1 3918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.